Vincerebio
Founded 2018 · 10 employees on LinkedIn · 5 known investors
Vincere Biosciences develops small-molecule therapeutics targeting mitochondrial quality control and mitophagy, primarily for neurodegenerative diseases including Parkinson's disease. The company translates computational biology and drug discovery into disease-modifying treatments for CNS disorders.
Investors · 5
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $470.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $299.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $252K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Vincerebio do?
- Vincere Biosciences develops small-molecule therapeutics targeting mitochondrial quality control and mitophagy, primarily for neurodegenerative diseases including Parkinson's disease. The company translates computational biology and drug discovery into disease-modifying treatments for CNS disorders.
- Who are Vincerebio's investors?
- Vincerebio's investors include Beiersdorf Innovation Fund, Beresford Ventures, Draper Associates, Portal Innovations, quadraScope Venture Fund.